A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis

10.5K views

⸱

DOI:

10.3791/53585

⸱

March 25th, 2016

 ,  , 
1David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY

In This Article

Summary

The mechanisms that govern the interstitial motility of CD4 effector T cells at sites of inflammation are relatively unknown. We present a non-invasive approach to visualize and manipulate in vitro-primed CD4 T cells in the inflamed ear dermis, allowing for study of the dynamic behavior of these cells in situ.

Abstract

The ability of CD4 T cells to carry out effector functions is dependent upon the rapid and efficient migration of these cells in inflamed peripheral tissues through an as-yet undefined mechanism. The application of multiphoton microscopy to the study of the immune system provides a tool to measure the dynamics of immune responses within intact tissues. Here we present a protocol for non-invasive intravital multiphoton imaging of CD4 T cells in the inflamed mouse ear dermis. Use of a custom imaging platform and a venous catheter allows for the visualization of CD4 T cell dynamics in the dermal interstitium, with the ability to interrogate these cells in real-time via the addition of blocking antibodies to key molecular components involved in motility. This system provides advantages over both in vitro models and surgically invasive imaging procedures. Understanding the pathways used by CD4 T cells for motility may ultimately provide insight into the basic function of CD4 T cells as well as the pathogenesis of both autoimmune diseases and pathology from chronic infections.

Introduction

The effector function of CD4 T cells is critically dependent on their ability to rapidly enter and traverse a wide variety of peripheral tissues to survey for damage, locate foci of infection, or cause pathology from chronic infection or autoimmunity. While the processes of homing to inflamed sites1-4 and extravasation5-7 from the vasculature into tissues have been well-characterized, the factors that drive and regulate the interstitial motility of T cells remain undefined. The migration of T cells in complex 3D environments has been studied in vitro through the use of artificial matrices8-10 or microfluidic devices11,12, but these fail to recapitulate the complex and dynamic environment of an in vivo system. It is only recently, with the advent of high-resolution multi-color intravital imaging that it has become possible to study the dynamic behavior of immune cells in situ, allowing for a better understanding of intact immune responses.

Over a decade ago, several influential studies were published that first utilized multiphoton microscopy to address immunological questions. Early studies focused on the behavior of immune cells within explanted lymphoid organs13-16, which were soon followed by techniques to image exposed lymph nodes in anesthetized mice17. Imaging allowed for new fundamental observations about the stages of lymph node priming of T cells18, the mechanisms by which T cells migrate in secondary lymphoid organs19, T cell interactions with other immune cells20,21, and dynamic T cell positioning within the lymph node22. Although many early studies focused on lymph node dynamics, intravital imaging has been since been utilized to image the immune response in many peripheral tissues, including the brain23-25, liver26, lung27, and skin28-30.

The mouse ear dermis is particularly well poised for imaging, due to the thinness of ear skin, a relative lack of hair, and the ease with which it can be isolated from respiratory movements31. Indeed, the ear dermis has been used to image the interstitial behavior of dendritic cells32,33, T cells28,29,34,35, and neutrophils36,37, and is a well-established site for studying dermal inflammation. Increasingly, non-invasive procedures have been replacing surgical preparations of the skin, including split dermis38,39, flank39,40, or dorsal skin flap window39,41 models, that can induce changes to the local inflammatory milieu. The use of transferred, in vitro-primed, antigen-specific CD4 effector T cells allows for the study of a homogenous population of cells in the context of a dermal inflammatory response30. Here we describe a non-invasive imaging procedure that allows for the visualization of antigen-specific effector CD4 T cells in the dermal interstitium of the inflamed mouse ear, and the ability to manipulate these cells in real-time by introducing blocking antibodies through a venous catheter. We show that this model is effective for tracking the movement of CD4 T cells in the dermis and for querying the mechanisms that govern this motility.

Access restricted. Please log in or start a trial to view this content.

Protocol

All procedures involving mice were approved by the Institutional Animal Care and Use Committee of the University of Rochester, and carried out in strict accordance with the Animal Welfare Act and the Public Health Service Policy on Humane Care and Use of Laboratory Animals administered by the National Institutes of Health, Office of Laboratory Animal Welfare.

1. Preparation of Effector CD4 T Cells

NOTE: BALB/c TCR-transgenic DO11.10 mice that specifically recognize a peptide from chicken egg ovalbumin (pOVA: ISQAVHAAHAEINEAGR). Other TCR-transgenic systems can be substituted, using the appropriate cognate peptide in place of pOVA where indicated.

  1. Purify naïve CD4 T cells
    1. Euthanize a 6-8 week-old female DO11.10 BALB/c mouse by exposing to 2 L/min CO2 until the mouse shows no signs of movement or breathing for 1 min, followed by cervical dislocation, or according to the guidelines of the local Institutional Animal Care and Use committee. Spray the mouse with a 70% ethanol solution and make an approximately 7 cm incision in the skin from the chin of the mouse to 2/3 of the way down the abdomen. Make 2-3 cm skin incisions from the end of the incision in the abdomen towards the hind feet. Be careful not to cut into the peritoneum.
    2. Carefully separate the skin from the peritoneum by gently pulling with forceps. The inguinal lymph nodes are located on the skin near the junction of the hind legs with the body. Remove by grasping and pulling with forceps and place in 8 ml of HBSS supplemented with 2% newborn calf serum (NCS).
    3. Harvest the axillary and brachial lymph nodes from the mouse by grasping and pulling gently with forceps. Place in the HBSS +2% NCS with the inguinal lymph nodes.
    4. Harvest the deep and superficial cervical lymph nodes located in the neck of the mouse with forceps and place in the HBSS + 2% NCS with the other lymph nodes.
    5. Gently cut into the peritoneum, taking care not to cut into the intestines. Grasp the cecum and colon with forceps and expose the mesenteric lymph nodes that are located just along the colon. Carefully remove the mesenteric lymph nodes with forceps and place with the other lymph nodes.
    6. Locate the spleen in the peritoneal cavity and carefully remove it, holding with forceps and cutting the connective tissue away with a pair of surgical scissors. Place the spleen with the lymph nodes.
    7. Prepare a single cell suspension by pouring the HBSS + 2% NCS containing the spleen and lymph nodes into a metal strainer placed in a 60 x 15 mm culture dish. Gently mash the spleen and lymph nodes through the metal strainer with the plunger from a 10 ml syringe into the HBSS + 2% NCS.
    8. Using a pipette, move the cell suspension into a clean 50 ml centrifuge tube. Rinse the metal strainer and culture dish with an additional 10 ml of HBSS + 2% NCS, using a pipette, and place this solution in the same 50 ml centrifuge tube as the cell suspension.
    9. Spin the cells at 600 x g for 5 min to pellet the cells and resuspend in 10 ml HBSS + 2% NCS by gently pipetting. Unless otherwise specified, all centrifugation should be performed at 600 x g for 5 min.
    10. Dilute 10 µl of the cell suspension in 90 µl of 0.1% trypan blue in PBS for a 1:10 dilution. Place 10 µl of the cells in trypan blue onto a hemocytometer by pipetting the solution into the groove at the edge of the hemocytometer. Count the white blood cells in the center grid of the hemocytometer, ignoring erythrocytes that appear as slightly smaller, round, red-hued cells and the blue dead/dying cells. Multiply the number of cells counted by 104, by the dilution factor (10), and by the volume of the cells (10 ml) to determine the total number of cells collected in the 50 ml centrifuge tube.
    11. To enrich for CD4 T cells, centrifuge the cells to pellet, and resuspend the cells at 2x107 cells/ml in a solution containing approximately 1 µg/ml anti-CD8 (clone 3.155), 1 µg/ml anti-MHC Class II (clone M5/114), and 1 µg/ml anti-CD24 (clone J11d) antibodies in HBSS + 2% NCS by gently pipetting.
      NOTE: The antibodies used in this step are derived in-house from hybridoma cell lines and concentrations are approximated. The concentration and volume of these antibodies ideal for complement lysis were determined empirically and will vary between labs. Alternatively, several commercially available kits are available for purification of naïve CD4 T cells and can be substituted for the complement lysis and CD62L+ purification process represented here. If using another method to purify naïve CD4 T cells, this protocol can be continued from step 1.2.
    12. Incubate on ice for 30 min. At the end of this incubation, rapidly thaw guinea pig complement by placing in a 37 °C water bath for approximately 2 min. Add 100 µl of complement for every 1 ml of cells in the antibody solution by pipetting the complement directly into the cell suspension. Incubate cells in a 37 °C water bath for 30 min.
    13. Add HBSS + 2% NCS to bring the cells to a total volume of 20 ml in the centrifuge tube. Layer in 8 ml of RT density centrifugation media (density 1.086 g/ml) underneath the cells. Immediately centrifuge the cells at 1400 x g at RT for 15 min with the centrifuge brake off.
    14. Collect cells at the interface using a serological pipette and transfer cells to a new 50 ml centrifuge tube. Wash the cells by bringing the volume in the centrifuge tube to 50 ml with HBSS + 2% NCS and centrifuging.
    15. Resuspend the cells in MACS buffer (PBS supplemented with 2% NCS and 2 mM EDTA) by gently pipetting and count as previously, in step 1.1.10.
    16. To enrich for naïve CD4 T cells, resuspend the cells at 2x107 cells/ml in a solution of 2.5 µg/ml biotin-conjugated anti-CD62L antibody in MACS buffer, based on the number counted in step 1.1.16. Incubate for 30 min on ice.
    17. Wash the cells by adding 10 ml MACS buffer, then centrifuging the cells. Resuspend the cells at 107 cells/100 µl in MACS buffer and add streptavidin-conjugated magnetic separation beads at a 1:10 dilution directly to the cells. Incubate on ice for 20 min.
    18. Wash the cells as before, in step 1.1.17, and resuspend the cells at 2x108 cells/ml in MACS buffer, in a minimum volume of 500 µl.
    19. Place a magnetic separation column in the magnet holder and wash the column by letting 3 ml MACS buffer flow through. Apply the cells to the column with a pipette.
    20. Wash the column to remove cells not bound by the magnetic column by pipetting 3 ml MACS buffer onto the column and allowing the MACS buffer to flow through, and repeat 3 times. Discard the flow through fraction.
    21. Remove the column from the magnetic stand and hold over a new 50 ml centrifuge tube. Pipet 5 ml of MACS buffer onto the column and use the plunger enclosed with the column to push the MACS buffer through the column to release the column bound cells and collect the flow through that contains the enriched naïve CD4 T cells.
    22. Centrifuge the cells and resuspend in 10 ml RPMI supplemented with 10% Fetal calf serum (FCS), 100 I.U./ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 50 µM 2-mercaptoethanol (RPMI-10). Count the cells as before, in step 1.1.10.
    23. Adjust the final concentration of the naïve CD4 T cells to 6x105/ml in RPMI-10.
  2. Purify T cell-depleted splenic APCs
    1. Euthanize a 6-8 week-old female wild-type BALB/c mouse as in step 1.1.1.
    2. Spray the mouse with a 70% ethanol solution and expose the spleen by making an approximately 3 cm incision on the left side of the mouse's abdomen. Cut open the peritoneal layer and remove the spleen by gently grasping it with forceps and cutting it away from the underlying connecting tissue with a surgical scissors.
    3. Place the spleen into 8 ml of HBSS + 2% NCS.
    4. Prepare a single cell suspension by mashing the spleen, wash, and count the cells, as before, in steps 1.1.7-1.1.10
    5. Deplete T cells by spinning the cells at 600 x g for 5 min to pellet, and resuspend the cells at 2x107 in a solution of approximately 1 µg/ml anti-Thy1.2 antibody (J1J clone) by gently pipetting. Incubate the cells on ice for 30 min.
      NOTE: This antibody was derived in-house from a hybridoma cell line and the concentraton is approximated. The concentration and volume of this antibody ideal for complement lysis was determined empirically and will vary between labs. Other methods for purifying APCs from splenocytes can be substituted if desired. Naïve T cells and APCs should be prepared in culture from step 1.3.
    6. Add guinea pig complement, incubate, and separate the cells on a density centrifugation media gradient as before, in steps 1.1.13-1.1.14.
    7. Resuspend the cells in 10ml of RPMI-10 and irradiate the APCs by placing the cells in a 50 ml centrifuge tube into a gamma irradiator for a length of time that will expose the cells to 25 Gy radiation. This length of time will vary based on the irradiator and will need to be calculated every time cells are irradiated.
    8. Count the cells on a hemocytometer as before, in step 1.1.10, and adjust the APC cells to a final concentration of 2.4x106 cells/ml in RPMI-10.
  3. Stimulate cells and differentiate CD4 T cells to a Th1 phenotype in a 5-day culture.
    NOTE: Although we present here a protocol for preparing and imaging Th1 effectors generated from naïve CD4 T cells, this protocol can be adjusted to differentiate the naïve cells to a different phenotype, or to use other cell types, such as CD8 T cells. Conditions for priming and differentiation will have to be determined empirically.
    1. In each well of a 24-well culture dish, combine 500 µl of the naïve CD4 T cells and 500 µl of the irradiated APCs in each well, for a total of 3x105 T cells and 1.2x106 APCs per well.
    2. Prepare a solution in RPMI-10 containing 2 µM cognate OVA peptide, 20 U/ml recombinant IL-2, 80 µg/ml anti-IL-4 (clone 11B11) and 40 ng/ml recombinant IL-12 and filter using a 0.2 µm syringe filter. Add 1ml of this solution to each well of cells, for a total volume of 2 ml in each well.
    3. Incubate the cells in a 37 °C incubator at 5% CO2 for 3 days.
    4. On day 3, split the cultures by gently pipetting to resuspend cells and moving 1 ml from each well into a new culture well. Bring each well to a final volume of 2 ml by adding 1 ml/well of RPMI-10 + 20 U/ml recombinant IL-2.
    5. Return the plates to the incubator and allow the cells to expand until day 5.

2. Transfer of Cells and Induction of Inflammation

NOTE: For optimal cell numbers for imaging, 5x106 fluorescently labeled Th1 cells should be transferred to each mouse in a total volume of 200 µl PBS. Cells here are labeled with the green dye CFSE or the near-red dye CMTMR, although other cell tracker dyes can be used. CFSE and CMTMR-labeled cells can be co-transferred to allow for tracking of two distinct effector CD4 populations.

  1. Label effector T cells with CFSE
    1. Harvest the cells from the culture dishes by vigorously pipetting the cells in each well and transferring to a sterile 50ml centrifuge tube with a pipet. Count the cells as in step 1.1.10, then centrifuge and resuspend the cells at 107 cells/ml in PBS + 5% NCS.
    2. Dilute 5 mM stock CFSE solution 1:100 in PBS. Add 110 µl CFSE solution for each 1 ml of cells by placing a drop of CFSE solution on the side of the tube and then rapidly rocking the tube back and forth to thoroughly mix.
    3. Incubate the cells for 5 min at RT, then quench the CFSE by adding 5 ml of fetal calf serum (FCS) directly to the tube of cells. Bring the volume to 50 ml with PBS + 5% NCS.
    4. Centrifuge the cells and resuspend the pellet in 20 ml PBS + 5% NCS. Repeat this process two more times to wash the cells 3 times total. Count the cells on a hemocytometer, as before, in step 1.1.10, and resuspend the cells in sterile PBS at 2.5 x 107 cells/ml for transfer to mice.
  2. Label effector T cells with CMTMR
    1. Harvest the cells as above in step 2.1.1, then count, centrifuge and resuspend the cells at 107 cells/ml in RPMI-10.
    2. Add 10 mM CMTMR stock solution directly to the cells for a final concentration of 10 µM. Quickly pipet the cells to thoroughly mix in the CMTMR and prevent precipitation of the dye.
    3. Incubate 30 min in a 37 °C water bath. Wash cells 3x in PBS + 5% NCS as before, in step 2.1.3-2.1.4. Count and resuspend the cells in sterile PBS at 2.5x107 cells/ml for transfer to mice.
  3. Transfer effector T cells to naïve 6-8 week old female BALB/c mice.
    1. Draw the cell suspension (step 2.1.4 or 2.2.3) into a syringe, taking care to remove all bubbles by holding the syringe needle side-up, gently flicking the side of the syringe and moving the plunger up and down, if necessary.
    2. Place mice in a clean cage and heat gently under a heat lamp until the tail vein appears vasodilated. Place the mouse in a restraining device and wipe the tail with an alcohol swab. Slowly inject 200 µl of the cell suspension into the lateral tail vein. There should be no resistance to injection or visible bubbling under the skin.
  4. Induce dermal inflammation by immunizing with Complete Freund's Adjuvant (CFA)
    NOTE: In this protocol, inflammation is induced by intradermal injection of CFA emulsified with either cognate or non-cognate antigen. Other inflammatory models can be substituted, although the number of cells required for transfer and the timing of imaging will need to be adjusted empirically.
    1. Prepare a 200 µM solution of OVA peptide in sterile PBS in a microcentrifuge tube. Pipet an equivalent volume of CFA on top of the peptide solution.
    2. Emulsify the solution by drawing it into a 28 G1/2 insulin syringe and then plunging the solution back into the microcentrifuge tube, then repeating this action approximately 20 times. When fully emulsified, the CFA and peptide solution will form a thick and opaque mixture.
      NOTE: it is essential to use a fixed-needle insulin syringe to form the emulsion, as the emulsion will be lost in the dead space in a non-fixed needle syringe.
    3. Test the emulsion by dropping a small amount onto water placed in a petri dish. The emulsion should remain intact and not disperse into the water.
    4. Draw the emulsion into a 300 µl 28 G1/2 insulin syringe and press down sharply on the plunger to remove large air bubbles.
    5. Immediately after the transfer of fluorescently labeled effector T cells, anesthetize the mice by i.p. injection of 2,2,2-tribromoethanol at 240 mg/kg. Assess anesthesia by a gentle toe pinch, administering more 2,2,2-tribromoethanol in 1 mg increments, if necessary.
      NOTE: other approved anesthetics may be substituted for the 2,2,2-tribromoethanol.
    6. Place a thimble on the left index finger and carefully grasp the mouse's ear between the left thumb and index finger with the ventral ear facing up. Make sure not to exert excessive pressure on the ear, which can cause mechanical damage to the skin.
    7. Slide the needle containing the CFA emulsion into the dermis, bevel side facing up, and slowly inject 10 µl of the emulsion into the ear. Placement of the injection should be in the outer 1/3 of the pinna, slightly off-center to allow for optimal imaging.
    8. Monitor mice until the anesthesia has worn off and mice are able to right themselves and are ambulatory. Image mice 3 days following immunization, providing time for inflammation to develop and the transferred T cells to traffic to the ear dermis.
      NOTE: Mice may not be left unattended at any time while under anesthesia.

3. Preparing the Mouse for Imaging

  1. Prepare a catheter
    1. Carefully remove the metal needle from a 30 G1/2 Tuberculin (TB) syringe needle with pliers and clean off any excess glue, using a dissecting scope to visualize that the glue is completely removed.
    2. Cut the tip off of another 30 G1/2 TB syringe needle, ensuring that the remaining needle is still patent by visual inspection. Slip an 18 cm piece of PE-10 medical tubing onto the trimmed needle, and carefully place the bare metal needle approximately 5 mm into the other end of the tubing, creating a catheter.
  2. Flush the catheter by filling a 1 ml TB syringe with sterile PBS, removing any air bubbles. Gently place the catheter on the tip of the syringe and push PBS gently though the catheter to remove any bubbles in the tubing.
    NOTE: when pushing fluid through the catheter, it is essential to hold the catheter on the syringe to prevent fluid pressure from pushing the catheter off of the syringe.
  3. Place mice in a clean cage and heat gently under a heat lamp until the tail vein appears vasodilated. Anesthetize the mouse with a mixture of room air and isoflurane (5% induction, 1-2% maintenance, at 2 L/min flow rate), delivered through the nosecone assembly that has been attached to the isoflurane vaporizer. Ensure that the mouse is anesthetized with a gentle toe pinch. Incrementally increase the isoflurane flow rate by 0.1% if movement is observed. Cover the eyes with ophthalmic ointment to prevent drying and injury while the mouse is anesthetized.
    NOTE: It is essential that mice never be left unattended while anesthetized. Mice should be frequently monitored for sufficient anesthesia by gentle toe pinch.
  4. Immobilize the tail at the base with a pair of forceps, and then wipe the tail with an alcohol swab. Carefully slide the catheter into the lateral tail vein and check patency by gently pushing on the plunger of the syringe. There should be no resistance to movement and no visible bubbling of PBS under the skin if it is appropriately placed. Affix the catheter to the tail by applying 1-2 drops of cyanoacrylate tissue adhesive to the injection site and allow to dry, approximately 30 sec.
  5. Carefully trim the hair from the back and sides of the ear with a pair of scissors, taking care not to damage the skin. Trim the whiskers as well. Using a cotton swab, moisten the inner surface of the ear with PBS.
  6. Rotate the mouse and ear onto a 24 x 50 mm No. 1.5 glass cover slip. Using forceps, gently flatten the ear onto the cover slip, moving the mouse if necessary to ensure that the ear is flush with the glass. Remove excess PBS from the ear by blotting gently with a tissue wipe.
    NOTE: Make sure not to press too firmly on the ear, as the thin skin can be easily damaged with excessive pressure.
  7. Using two pairs of curved forceps, grasp an approximately 20 mm long piece of fabric tape lengthwise at the top corners. Place the bottom of the tape onto the coverslip at the top of the mouse's ear and roll the tape over the rest of the ear, pushing excess hair out of the way with the forceps if necessary to affix the ear to the coverslip. Gently press on the tape around the ear with a dry cotton swab to ensure a tight seal, taking care not to press on the ear itself.
  8. Attach the imaging platform to a 37 °C heating block with adhesive tape. Apply vacuum grease on either side of the ear area of the imaging platform. Rotate the mouse to place the coverslip onto the imaging platform, taking care to align the ear in the center of the felt.
    NOTE: Avoid getting vacuum grease on the tape, as this will cause it to come detached from the glass cover slip.
  9. Snap the isoflurane nosecone into the holder on the imaging platform, ensuring that the nosecone is secure and completely covering the mouse's nose. Spread the vacuum grease under the coverslip by firmly but carefully pressing the coverslip onto the imaging platform with a clean, dry cotton swab.
  10. Affix the coverslip to the platform with two 20 mm pieces of tape and two longer pieces of tape wrapped around the upper portion of the platform. If any air bubbles are present between the ear and the coverslip, they can be gently removed by pressing on the ear from below with a piece of folded paper.
    NOTE: It is essential not to use paper that is too thick or to press firmly, as this can cause tissue blanching and damage, complicating results.
  11. Move the mouse to the microscope stage and secure the platform with adhesive tape. Pipe a double layer of vacuum grease onto the coverslip around the ear to serve as a reservoir for the water immersion objective.
  12. Wrap a water-filled heating blanket around the mouse through the imaging platform. Fill the reservoir with 37 °C distilled water. Ensure that everything is secured to the stage with adhesive tape and that the syringe of the catheter is easily accessible.

4. In Vivo Time-lapse Imaging and Intravenous Antibody Administration

NOTE: This protocol requires the use of a multiphoton microscope equipped with a Ti:Sa laser system. The objective used is a 25x magnification lens with 1.05 N.A., affixed with an objective heater set to 40 °C. The optimal temperature for this heater was determined empirically to be the appropriate temperature to maintain the ear dermis at 37 °C, and may need to be adjusted for use in other imaging systems. The acquisition software used may vary between instruments and adjustments to the protocol may have to be made to work on differently configured systems. Ensure that images can be saved in a format that is compatible with any desired analysis software.

  1. Locate the dermis through the eyepieces by positioning the objective over the center of the ear and lowering the objective just until it contacts the surface of the water in the reservoir. Using an external light source, look through the eyepieces and continue to slowly lower the objective until the surface of the ear comes into focus. Lower the inner and outer curtains around the microscope stage.
  2. Determine microscope settings and locate an area for imaging
    1. Before imaging, configure the laser for maximal excitation and detection of the desired fluorophores by adjusting the laser wavelength to 900 nm in the MP Laser Controller window, the laser power in the Acquisition Setting: Laser window, and the PMT voltages in the Image Acquisition Control window.
      NOTE: This procedure uses an excitation wavelength of 900 nm with filters to detect second harmonic generation (420-460 nm), CFSE (495-540 nm), and CMTMR (575-630 nm). Other configurations can be used to detect different fluorophores as desired.
    2. Set the microscope to 512 x 512 pixel resolution, with a 2 µsec/pixel dwell time in the Acquisition Setting: Size and Mode windows. Activate a live imaging mode to allow scanning through the tissue for an area to image by clicking "XY repeat". Ideally, the area should be relatively uniform, without air bubbles, and avoiding areas of dense hair follicles.
      NOTE: The CFA emulsion is brightly autofluorescent in the green and near-red channels and should be avoided. An optimal field can usually be found approximately 3 mm from the edge of the emulsion. Approximately 10 - 100 cells can be tracked in a single image. If too many cells are present, tracking software will generally encounter errors in attempting to separate closely located cells, leading to shortened and/or inaccurate cell tracks.
    3. Once an appropriate imaging field has been located, determine the Z region that will be imaged by locating the cell "highest" in the dermis, setting the Z-position to 0 by clicking the "Set 0" button, and scrolling down in the Z direction to measure extent of cell depth. An imaging depth of 35-75 µm is typical. Set the starting and end positions in the Acquisition Setting: Microscope window. Adjust the instrument PMT voltages and laser power in the "bright Z" window to optimize visualization of the cells throughout the depth of the imaging field.
      NOTE: Avoid raising the laser power above 25 mW at the sample, as high power levels can cause heat damage and sterile injury to the dermis. The appropriate maximum power level for each microscope will vary and will have to be measured. It should be noted that increasing laser power or PMT voltages with tissue depth does not allow for quantitative comparison of image brightness at different depths in post-acquisition analysis.
    4. Check the "Depth" and "Time" buttons underneath the "Scan" button in the Image Acquisition Control window. Set a Kalman filter to scan the image 3 times per line in the Image Acquisition Control: Filter Mode window and adjust the Z-slice depth in the Image Acquisition: Microscope window so that it takes approximately 1 min to capture a complete stack, as noted in the TimeView window.
      NOTE: The interval between stacks should not take longer than approximately 1 min, as longer intervals prevent the tracking of rapidly migrating cells. Depending on the type of cells being imaged, this interval may need to be adjusted to allow for proper cell tracking by analysis software. Z-slices should be no more than 5 µm. Generally 15-18 Z-slices between 2-5 µm thick are appropriate for a 1 min imaging interval.
  3. Capture a pre-antibody time-lapse image
    1. Capture a 5 min time-lapse image of the area to assess the stability of the tissue by setting the number of repeats to "5" in the Acquisition Setting: TimeScan window and clicking the "Scan" button.
      NOTE: Tissue "drift" can be caused by not allowing sufficient time for the ear to reach thermal equilibrium, poor ear preparation, or can be due to local drift in one region of the ear. If the 5 min image is not stable, image a new region in the dermis. If a second image in a new region remains unstable, it is best to carefully repeat the ear preparation and imaging from step 3.6 with a fresh coverslip.
    2. If the tissue is stable in the 5 min image, collect a 30-45 min time-lapse image by setting the number of repeats to between 30 and 45 in the Acquisition Setting: TimeScan window, monitoring for any minor tissue drift as the image is collected. Save the file in a format that is compatible with the analysis software to be used.
      NOTE: At this point in the protocol, steps 4.2.2 - 4.3.2 can be repeated to image multiple locations in the same ear. A single mouse should not be kept anesthetized for longer than 4 hr, as death is more likely to occur.
  4. Inject blocking antibodies and capture a post-antibody image.
    1. Draw the antibody mixture into a 1 ml TB syringe and remove the needle, making sure to remove all air bubbles. Press on the plunger so that the antibody solution forms a "droplet" at the end of the syringe.
    2. Lift the curtains around the stage and locate the catheter. Remove the original PBS-containing syringe from the catheter. Without setting the catheter down, carefully attach the new syringe containing the antibodies. Hold the end of the catheter onto the syringe and slowly inject the antibody mixture into the catheter. Ensure that there is no resistance to injection.
    3. Set the catheter down and lower the curtains surrounding the microscope stage. Note the time of injection and immediately start collecting a new 20-40 min imaging sequence in the same location using the same instrument settings as the pre-antibody image. Save the file in an appropriate format for the analysis software to be used.
      NOTE: Between time-lapse images, observe the mouse for sufficient anesthesia and breathing. It is not recommended to image more than one field following administration of antibodies, as there can be variable rates of clearance of the antibody.
  5. Inject fluorescently-labeled dextran to locate blood vessels, assess catheter patency, and measure blood vessel permeability
    1. Prepare a 2 mg/ml solution of fluorescently-conjugated dextran (70,000 MW) in 100 µl sterile PBS and draw into a syringe, removing any air bubbles.
    2. Using the same technique as in step 4.4.1-4.4.2, place the syringe onto the catheter and inject the dextran solution intravenously.
    3. Capture a single stack at 1024 x 1024 pixel resolution by changing the resolution in the Acquisition Setting: Mode window, with the same PMT and laser settings as for the time-lapse images. To collect the image, uncheck the "Time" button underneath the "Scan" button, and then clicking the "Scan" button. This 3D image will allow for the exclusion T cells located in the vasculature and show that the catheter was patent and properly inserted. The diffusion of fluorescent dextran out of the vessels can be also used to assess local vascular permeability.
      NOTE: This high-resolution (1024 x 1024) static image is used for presentation purposes and can be additionally be used for analysis of the tissue architecture in the same area as the time-lapse images. Alternatively, a 512 x 512 image can be taken, which can be merged with the time-lapse images using image analysis software. Time lapse imaging of the dextran administration may also be desired, depending on the research needs of individual labs. In this case, the image should be set up as in steps 4.2.3-4.3.2.
  6. After imaging is completed, carefully remove the mouse from under the objective and unwrap the water blanket. Remove the coverslip from the imaging platform by cutting the tape and gently lifting the glass until it detaches. While the mouse is still anesthetized, detach the ear from the coverslip. If this is to be a terminal procedure, euthanize the mouse by cervical dislocation. If saving this mouse for repeated imaging, return it to a clean cage separate from other mice and observe until the mouse can right itself and is ambulatory. Once recovered from anesthesia, the mouse can be returned to a cage with other animals.
  7. Import the imaging files into an image analysis program and perform any desired corrections. Avoidance of non-linear enhancements and automated smoothing or noise reduction programs and algorithms is recommended. Typically, images need only a minor background correction by manually increasing the black point of the image before analysis. Analyze the imaging data by using an automated cell-tracking program with manual correction, as in Overstreet, Gaylo et al30.  
    NOTE: There are many image analysis suites available, both proprietary and open source, that can be used to quantify cell dynamics from the multiphoton images derived from this protocol. The exact method of image analysis and the optimal software packages to be used will depend on the research needs of individual laboratories.

Access restricted. Please log in or start a trial to view this content.

Results

The ability to study immune responses in situ without altering the immune environment is essential in studying real-time interactions of T effector cells with an inflamed tissue. Imaging of the intact ear dermis by this protocol, outlined in Figure 1A and B, allows for the visualization of transferred fluorescently labeled T effector cells in the dermal interstitium. This permits both high-resolution (Figure 1C) and time-lapse (<...

Access restricted. Please log in or start a trial to view this content.

Discussion

Significance

Here we present a complete protocol for the 4D visualization of transferred, antigen-specific effector Th1 cells in the intact mouse ear dermis. This method provides advantages over some current imaging modalities for several reasons. By imaging the ventral ear dermis, we are able to forego hair removal that is required for imaging protocols involving other skin sites. Although depilatories are generally mild, they have been shown to cause disruption to the skin barrier <...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose. 

Acknowledgements

The authors thank the University of Rochester Multiphoton Microscope Core facility for help with live imaging. Supported by NIH AI072690 and AI02851 to DJF; AI114036 to AG and AI089079 to MGO.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
BALB/c miceJackson Laboratories000651Mice used were bred in-house
DO11.10 miceJackson Laboratories003303Mice used were bred in-house
HBSSFisher10-013-CVMultiple Equivalent
Newborn Calf Serum (NCS)Thermo/HyCloneSH30118.03Heat inactivated at 56 °C for 30 minutes
Guinea Pig ComplementCedarlaneCL-5000
anti-CD8 antibodyATCC3.155 (ATCC TIB-211)Antibodies derived from  this hybridoma
anti-MHC Class II antibodyATCCM5/114.15.2 (ATCC TIB-120)Antibodies derived from  this hybridoma
anti-CD24 antibodyATCCJ11d.2 (ATCC TIB-183)Antibodies derived from  this hybridoma
anti-Thy1.2 antibodyATCCJ1j.10 (ATCC TIB-184)Antibodies derived from  this hybridoma
Ficoll (Fico/Lite-LM)Atlanta BiologicalsI40650
PBSFisher21-040-CVMultiple Equivalent
EDTAFisher15323591
biotinylated anti-CD62L antibody (clone MEL-14)BD553149
streptavidin magnetic separation beadsMiltenyi130-048-101
MACS LS Separation ColumnMiltenyi130-042-401
recombinant human IL-2Peprotech200-02
recombinant mouse IL-4Peprotech214-14
recombinant mouse IL-12Peprotech210-12
anti-IFNg antibody (clone XMG 1.2)eBioscience16-7311-85
anti-IL-4 antibody (clone 11b11)eBioscience16-7041-85
RPMIVWR45000-412
Penicillin/StreptomycinFisher15303641
L-glutamineFisher15323671
2-mercaptoethanolBio-Rad161-0710
ovalbumin peptideBiopeptideISQAVHAAHAEINEAGR-OH peptide
Fetal Calf Serum (FCS)Thermo/HyCloneSV30014.03Heat inactivated at 56 °C for 30 minutes
24-well culture plateLPS3526Multiple Equivalent
CFSELife TechnologiesC34554
CMTMRLife TechnologiesC2927
28 G1/2 insulin syringes, 1mlBD329420
28 G1/2 insulin syringes, 300μlBD309301
27 G1/2 TB syringes, 1mlBD309623
30 G1/2 needlesBD305106
PE-10 medical tubingBD427400
cyanoacrylate veterinary adhesive (Vetbond)3M1469SB
heating plateWPI61830
Heating plate controllerWPIATC-2000
Water blanket controllerGaymarTP500No longer in production, newer equivalent available
water blanketKent ScientificTP3E
Isoflurane vaporizerLEI MedicalIsotec 4No longer in production, newer equivalent available
isofluraneHenry ScheinOrdered through Veterinary staff
microcentrifuge tubesVWR20170-038Multiple Equivalent
medical tape3M1538-0
isoflurane noseconeBuilt In-house, see Fig 2
imaging platformBuilt In-house, see Fig 2
curved forcepsWPI15915-GMultiple Equivalent
scissorsRobozRS-6802Multiple Equivalent
glass coverslipsVWRMultiple Equivalent
high vacuum greaseFisher146355D
cotton swabsMultiple Equivalent
delicate task wipesFisher34155Multiple Equivalent
Olympus Fluoview 1000 AOM-MPM upright microscope with Spectra-Physics MaiTai HP DeepSee Ti:Sa laserOlympuscall for quote
optical table with vibration controlNewportcall for quote
25x NA 1.05 water immersion objective for multiphoton imagingOlympusXLPLN25XWMP2
objective heaterBioptechsPN 150815
Detection filter cubeOlympusFV10-MRVGR/XRProprietary cube, can be approximated from individual filters/dichroics
anti-integrin β1 antibody (clone hMb1-1)eBioscience16-0291-85Azide free, low endotoxin
anti-integrin β3 antibody (clone 2C9.G3)eBioscience16-0611-82Azide free, low endotoxin
Texas Red Dextran (70,000 MW)Life TechnologiesD-1830

References

  1. Denucci, C. C., Mitchell, J. S., Shimizu, Y. Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there. Critical reviews in immunology. 29 (2), 87-109 (2009).
  2. Gehad, A., et al. Differing requirements for CCR4, E-selectin, and alpha4beta1 for the migration of memory CD4 and activated T cells to dermal inflammation. Journal of immunology. 189 (1), 337-346 (2012).
  3. Park, E. J., et al. Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes. Blood. 115 (8), 1572-1581 (2010).
  4. Masopust, D., Schenkel, J. M. The integration of T cell migration, differentiation and function. Nature reviews. Immunology. 13 (5), 309-320 (2013).
  5. Valignat, M. P., Theodoly, O., Gucciardi, A., Hogg, N., Lellouch, A. C. T lymphocytes orient against the direction of fluid flow during LFA-1-mediated migration. Biophysical journal. 104 (2), 322-331 (2013).
  6. Schon, M. P., Ludwig, R. J. Lymphocyte trafficking to inflamed skin--molecular mechanisms and implications for therapeutic target molecules. Expert opinion on therapeutic targets. 9 (2), 225-243 (2005).
  7. Nourshargh, S., Alon, R. Leukocyte migration into inflamed tissues. Immunity. 41 (5), 694-707 (2014).
  8. Friedl, P., Entschladen, F., Conrad, C., Niggemann, B., Zanker, K. S. CD4+ T lymphocytes migrating in three-dimensional collagen lattices lack focal adhesions and utilize beta1 integrin-independent strategies for polarization, interaction with collagen fibers and locomotion. European journal of immunology. 28 (8), 2331-2343 (1998).
  9. Wolf, K., Muller, R., Borgmann, S., Brocker, E. B., Friedl, P. Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. Blood. 102 (9), 3262-3269 (2003).
  10. Lammermann, T., et al. Cdc42-dependent leading edge coordination is essential for interstitial dendritic cell migration. Blood. 113 (23), 5703-5710 (2009).
  11. Jacobelli, J., et al. Confinement-optimized three-dimensional T cell amoeboid motility is modulated via myosin IIA-regulated adhesions. Nature immunology. 11 (10), 953-961 (2010).
  12. Jacobelli, J., Bennett, F. C., Pandurangi, P., Tooley, A. J., Krummel, M. F. Myosin-IIA and ICAM-1 regulate the interchange between two distinct modes of T cell migration. Journal of immunology. 182 (4), 2041-2050 (2009).
  13. von Andrian, U. H. Immunology. T cell activation in six dimensions. Science. 296 (5574), 1815-1817 (2002).
  14. Bousso, P., Bhakta, N. R., Lewis, R. S., Robey, E. Dynamics of thymocyte-stromal cell interactions visualized by two-photon microscopy. Science. 296 (5574), 1876-1880 (2002).
  15. Miller, M. J., Wei, S. H., Parker, I., Cahalan, M. D. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science. 296 (5574), 1869-1873 (2002).
  16. Stoll, S., Delon, J., Brotz, T. M., Germain, R. N. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science. 296 (5574), 1873-1876 (2002).
  17. Miller, M. J., Wei, S. H., Cahalan, M. D., Parker, I. Autonomous T cell trafficking examined in vivo with intravital two-photon microscopy. Proceedings of the National Academy of Sciences of the United States of America. 100 (5), 2604-2609 (2003).
  18. Mempel, T. R., Henrickson, S. E., Von Andrian, U. H. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature. 427 (6970), 154-159 (2004).
  19. Woolf, E., et al. Lymph node chemokines promote sustained T lymphocyte motility without triggering stable integrin adhesiveness in the absence of shear forces. Nature immunology. 8 (10), 1076-1085 (2007).
  20. Bousso, P., Robey, E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nature immunology. 4 (6), 579-585 (2003).
  21. Henrickson, S. E., et al. T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nature immunology. 9 (3), 282-291 (2008).
  22. Bajenoff, M., et al. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity. 25 (6), 989-1001 (2006).
  23. Kawakami, N., Flugel, A. Knocking at the brain's door: intravital two-photon imaging of autoreactive T cell interactions with CNS structures. Seminars in immunopathology. 32 (3), 275-287 (2010).
  24. Wilson, E. H., et al. Behavior of parasite-specific effector CD8+ T cells in the brain and visualization of a kinesis-associated system of reticular fibers. Immunity. 30 (2), 300-311 (2009).
  25. Schaeffer, M., et al. Dynamic imaging of T cell-parasite interactions in the brains of mice chronically infected with Toxoplasma gondii. Journal of immunology. 182 (10), 6379-6393 (2009).
  26. Egen, J. G., et al. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity. 28 (2), 271-284 (2008).
  27. Fiole, D., et al. Two-photon intravital imaging of lungs during anthrax infection reveals long-lasting macrophage-dendritic cell contacts. Infection and immunity. 82 (2), 864-872 (2014).
  28. Celli, S., Albert, M. L., Bousso, P. Visualizing the innate and adaptive immune responses underlying allograft rejection by two-photon microscopy. Nature medicine. 17 (6), 744-749 (2011).
  29. Matheu, M. P., et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 29 (4), 602-614 (2008).
  30. Overstreet, M. G., et al. Inflammation-induced interstitial migration of effector CD4(+) T cells is dependent on integrin alphaV. Nature immunology. 14 (9), 949-958 (2013).
  31. Li, J. L., et al. Intravital multiphoton imaging of immune responses in the mouse ear skin. Nature protocols. 7 (2), 221-234 (2012).
  32. Lammermann, T., et al. Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature. 453 (7191), 51-55 (2008).
  33. Teijeira, A., et al. Lymphatic endothelium forms integrin-engaging 3D structures during DC transit across inflamed lymphatic vessels. The Journal of investigative dermatology. 133 (9), 2276-2285 (2013).
  34. Sen, D., Forrest, L., Kepler, T. B., Parker, I., Cahalan, M. D. Selective and site-specific mobilization of dermal dendritic cells and Langerhans cells by Th1- and Th2-polarizing adjuvants. Proceedings of the National Academy of Sciences of the United States of America. 107 (18), 8334-8339 (2010).
  35. Gray, E. E., Suzuki, K., Cyster, J. G. Cutting edge: Identification of a motile IL-17-producing gammadelta T cell population in the dermis. Journal of immunology. 186 (11), 6091-6095 (2011).
  36. Lammermann, T., et al. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature. 498 (7454), 371-375 (2013).
  37. Ng, L. G., et al. Visualizing the neutrophil response to sterile tissue injury in mouse dermis reveals a three-phase cascade of events. The Journal of investigative dermatology. 131 (10), 2058-2068 (2011).
  38. Kilarski, W. W., et al. Intravital immunofluorescence for visualizing the microcirculatory and immune microenvironments in the mouse ear dermis. PloS one. 8 (2), 57135(2013).
  39. Chow, Z., Mueller, S. N., Deane, J. A., Hickey, M. J. Dermal regulatory T cells display distinct migratory behavior that is modulated during adaptive and innate inflammation. Journal of immunology. 191 (6), 3049-3056 (2013).
  40. Gebhardt, T., et al. Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature. 477 (7363), 216-219 (2011).
  41. Tozer, G. M., et al. Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. Advanced drug delivery reviews. 57 (1), 135-152 (2005).
  42. Lee, J. N., et al. The effects of depilatory agents as penetration enhancers on human stratum corneum structures. The Journal of investigative dermatology. 128 (9), 2240-2247 (2008).
  43. Brandt, E. B., Sivaprasad, U. Th2 Cytokines and Atopic Dermatitis. Journal of clinical & cellular immunology. 2 (3), (2011).
  44. Strid, J., Hourihane, J., Kimber, I., Callard, R., Strobel, S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. European journal of immunology. 34 (8), 2100-2109 (2004).
  45. Eriksson, E., Boykin, J. V., Pittman, R. N. Method for in vivo microscopy of the cutaneous microcirculation of the hairless mouse ear. Microvascular research. 19 (3), 374-379 (1980).
  46. Tong, P. L., et al. The skin immune atlas: three-dimensional analysis of cutaneous leukocyte subsets by multiphoton microscopy. The Journal of investigative dermatology. 135 (1), 84-93 (2015).
  47. Barker, J. H., et al. The hairless mouse ear for in vivo studies of skin microcirculation. Plastic and reconstructive surgery. 83 (6), 948-959 (1989).
  48. Zaid, A., et al. Persistence of skin-resident memory T cells within an epidermal niche. Proceedings of the National Academy of Sciences of the United States of America. 111 (14), 5307-5312 (2014).
  49. Stetson, D. B., et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. The Journal of experimental medicine. 198 (7), 1069-1076 (2003).
  50. Mohrs, M., Shinkai, K., Mohrs, K., Locksley, R. M. Analysis of type 2 immunity in vivo with a bicistronic IL-4 reporter. Immunity. 15 (2), 303-311 (2001).
  51. Moreau, H. D., et al. Dynamic in situ cytometry uncovers T cell receptor signaling during immunological synapses and kinapses in vivo. Immunity. 37 (2), 351-363 (2012).
  52. Cummings, R. J., Mitra, S., Lord, E. M., Foster, T. H. Antibody-labeled fluorescence imaging of dendritic cell populations in vivo. Journal of biomedical optics. 13 (4), 044041(2008).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Intravital ImagingMultiphoton MicroscopyT Cell MigrationMouse EarImaging PlatformAntibody InjectionTime LapseTissue Adhesive
Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis
Contact Us
Recommend to Library

Privacy

Terms of Use

Policies

Copyright © 2026 MyJoVE Corporation. All rights reserved.